Biozone Pharm (BZNE) 0.4100 $BZNE
Cocrystal Pharma reports change in stock symbol to reflect its merger with Biozone Pharmaceuticals
M2 - Thu Apr 17, 5:08AM CDT
Biotechnology company Cocrystal Pharma (OTC BB:COCP) (OTC BB:BZNE) said on Wednesday that its stock is now listed under the new ticker symbol "COCP" effective 15 April 2014.
Cocrystal Pharma, Inc. Announces Stock Symbol Change from BZNE to COCP
Marketwire - Wed Apr 16, 4:30PM CDT
Cocrystal Pharma, Inc. (the "Company"
(OTCQB: COCP) (OTCBB: BZNE), announced today that, effective April 15, 2014, the Company's stock began trading under the new symbol "COCP". The updated stock trading symbol marks the successful completion of the Company's recent merger with Biozone Pharmaceuticals, Inc., as announced on January 3, 2014.
Biozone Pharmaceuticals Inc raises USD2.75m in strategic investment
M2 - Fri Jan 24, 5:47AM CST
Biotechnology company Biozone Pharmaceuticals Inc (OTC BB:BZNE) reported on Thursday the receipt of USD2.75m from eight accredited investors, including OPKO Health (NYSE MKT:OPK).
Biozone Receives Strategic Investment From OPKO Health, Inc
Marketwire - Thu Jan 23, 8:30AM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE) today announced that it has raised $2,750,000 from eight accredited investors including OPKO Health (NYSE MKT: OPK).
MusclePharm Corporation acquires BioZone Pharmaceuticals' assets
M2 - Tue Jan 07, 5:52AM CST
Sports nutrition company MusclePharm Corporation (OTCQB:MSLP) revealed on Monday the completion of the acquisition of essentially all assets of BioZone Pharmaceuticals Inc (OTCBB: BZNE) and its subsidiaries, for 1.2m shares of MusclePharm stock.
MusclePharm Completes Acquisition of Substantially All Assets of BioZone Pharmaceuticals
Marketwire - Mon Jan 06, 7:31AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that it has completed the acquisition of essentially all assets of BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) and its subsidiaries, for 1.2 million shares of MusclePharm stock.
Biozone Pharmaceuticals Inc closes merger with Cocrystal Discovery
M2 - Mon Jan 06, 5:01AM CST
OTC drug products company Biozone Pharmaceuticals Inc (OTCQB:BZNE) said on Friday that it has finalised its planned merger with Cocrystal Discovery Inc.
UPDATE: Biozone Completes Acquisition of Cocrystal Discovery and Begins Transformation to High Growth Biotech Company
Marketwire - Fri Jan 03, 8:42AM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE) today announced that it has finalized its planned merger with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has previously received strategic investments from Teva Pharmaceuticals (NYSE: TEVA), Opko Health (NYSE MKT: OPK) and The Frost Group.
Biozone Completes Acquisition of Cocrystal Discovery and Begins Transformation to High Growth Biotech Company
Marketwire - Fri Jan 03, 7:00AM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE) today announced that it has finalized its planned merger with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has previously received strategic investments from Teva Pharmaceuticals (NYSE: TEVA), Opko Health (NYSE MKT: OPK) and The Frost Group.
BioZone Pharmaceuticals, Inc. Completes Balance Sheet Enhancement
Marketwire - Tue Dec 24, 7:00AM CST
BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) announced today that it has completed an enhancement of its balance sheet by eliminating remaining outstanding convertible notes. In the recent transaction, holders of convertible notes with approximately $2.5 million of principal and accrued interest exchanged their securities for shares of common stock. OPKO Health Inc. (NYSE: OPK), a principal shareholder of BioZone Pharmaceuticals and one of the note holders that converted its notes, expressed the view through its Chairman and CEO, Dr. Phillip Frost, that it is optimistic that the planned acquisition of Cocrystal Discovery will enhance shareholder value and enhance BioZone's future prospects as a high growth biotech company.
BioZone Pharmaceuticals, Inc. Enhances Balance Sheet
Marketwire - Mon Dec 02, 7:46AM CST
BioZone Pharmaceuticals, Inc. (OTCQB: BZNE) announced today that it has enhanced its balance sheet significantly by eliminating outstanding convertible preferred stock. In the recent transaction, holders of convertible preferred stock, with a stated value of $3.5 million and a 10% dividend, exchanged their securities for shares of common stock. Key holders expressed the view that the recently announced merger with Cocrystal Discovery, Inc. is a significant positive development for the Company.
Biozone Pharmaceuticals signs Letter of Intent to reverse merge with Cocrystal Discovery
M2 - Thu Nov 28, 4:44AM CST
Biozone Pharmaceuticals Inc (OTCBB:BZNE) announced on Wednesday its agreement to the terms and signed a Letter of Intent to merge with Cocrystal Discovery Inc, a biotechnology company developing antiviral therapeutics for human diseases.
Biozone Pharmaceuticals Announces Executed Letter of Intent to Merge With Cocrystal Discovery Inc.
Marketwire - Wed Nov 27, 7:00AM CST
Biozone Pharmaceuticals, Inc. (OTCBB: BZNE) today announced that it has agreed to terms and signed a Letter of Intent to merge with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has breakthrough technologies that enable the creation of first- and best-in-class antivirals.
LEVI & KORSINSKY, LLP Notifies Investors of BIOZONE PHARMACEUTICALS, INC. of Claims of Breaches of Fiduciary Duty by Board of the Company in Connection with the Sale of Assets to MusclePharm Corporation
Business Wire - Tue Nov 19, 12:11PM CST
Levi & Korsinsky notifies investors of Biozone Pharmaceuticals, Inc. ("Biozone" or the "Company" (Nasdaq: BZNE) of possible breaches of fiduciary duty and other violations of state law in connection with the sale of Company assets to MusclePharm Corporation ("MusclePharm" (OTCQB: MSLP).
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of the Biozone Pharmaceuticals, Inc. Proposed Asset Sale to MusclePharm Corporation
Business Wire - Tue Nov 19, 7:17AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether the Board of Directors of Biozone Pharmaceuticals, Inc. (Nasdaq: BZNE) breached its fiduciary duties in connection with the Company's proposed sale of assets to MusclePharm Corporation (OTCQB: MSLP).
Equity Reports on BZNE, NNRX and ENIP
ACCESSWIRE - Thu Nov 14, 4:16AM CST
Biozone Pharmaceuticals Inc. (OTC:BZNE), Nutranomics Inc. (OTC:NNRX) and Endeavor IP Inc. (OTC:ENIP) have been added to our watch list.
Biozone Announces First Step in Strategic Transition
Marketwire - Wed Nov 13, 2:19PM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE), a manufacturer of over-the-counter (OTC) pharmaceuticals, and skin care, cosmetic and beauty products, and developer of proprietary drug delivery platforms, issued the following Letter to Shareholders from Elliot Maza, Chief Executive Officer and CFO of the company.
MusclePharm to Acquire BioZone Pharmaceuticals' QuSomes(R) Technology and Manufacturing Facilities
Marketwire - Wed Nov 13, 7:03AM CST
MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm", a leading international, award-winning sports nutrition company, announced today it has signed a definitive asset purchase agreement with BioZone Pharmaceuticals, Inc. ("BioZone" to acquire substantially all of the assets of BioZone and its subsidiaries.
Cocrystal Pharma reports change in stock symbol to reflect its merger with Biozone Pharmaceuticals
M2 - Thu Apr 17, 5:08AM CDT
Biotechnology company Cocrystal Pharma (OTC BB:COCP) (OTC BB:BZNE) said on Wednesday that its stock is now listed under the new ticker symbol "COCP" effective 15 April 2014.
Cocrystal Pharma, Inc. Announces Stock Symbol Change from BZNE to COCP
Marketwire - Wed Apr 16, 4:30PM CDT
Cocrystal Pharma, Inc. (the "Company"
(OTCQB: COCP) (OTCBB: BZNE), announced today that, effective April 15, 2014, the Company's stock began trading under the new symbol "COCP". The updated stock trading symbol marks the successful completion of the Company's recent merger with Biozone Pharmaceuticals, Inc., as announced on January 3, 2014. Biozone Pharmaceuticals Inc raises USD2.75m in strategic investment
M2 - Fri Jan 24, 5:47AM CST
Biotechnology company Biozone Pharmaceuticals Inc (OTC BB:BZNE) reported on Thursday the receipt of USD2.75m from eight accredited investors, including OPKO Health (NYSE MKT:OPK).
Biozone Receives Strategic Investment From OPKO Health, Inc
Marketwire - Thu Jan 23, 8:30AM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE) today announced that it has raised $2,750,000 from eight accredited investors including OPKO Health (NYSE MKT: OPK).
MusclePharm Corporation acquires BioZone Pharmaceuticals' assets
M2 - Tue Jan 07, 5:52AM CST
Sports nutrition company MusclePharm Corporation (OTCQB:MSLP) revealed on Monday the completion of the acquisition of essentially all assets of BioZone Pharmaceuticals Inc (OTCBB: BZNE) and its subsidiaries, for 1.2m shares of MusclePharm stock.
MusclePharm Completes Acquisition of Substantially All Assets of BioZone Pharmaceuticals
Marketwire - Mon Jan 06, 7:31AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that it has completed the acquisition of essentially all assets of BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) and its subsidiaries, for 1.2 million shares of MusclePharm stock.
Biozone Pharmaceuticals Inc closes merger with Cocrystal Discovery
M2 - Mon Jan 06, 5:01AM CST
OTC drug products company Biozone Pharmaceuticals Inc (OTCQB:BZNE) said on Friday that it has finalised its planned merger with Cocrystal Discovery Inc.
UPDATE: Biozone Completes Acquisition of Cocrystal Discovery and Begins Transformation to High Growth Biotech Company
Marketwire - Fri Jan 03, 8:42AM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE) today announced that it has finalized its planned merger with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has previously received strategic investments from Teva Pharmaceuticals (NYSE: TEVA), Opko Health (NYSE MKT: OPK) and The Frost Group.
Biozone Completes Acquisition of Cocrystal Discovery and Begins Transformation to High Growth Biotech Company
Marketwire - Fri Jan 03, 7:00AM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE) today announced that it has finalized its planned merger with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has previously received strategic investments from Teva Pharmaceuticals (NYSE: TEVA), Opko Health (NYSE MKT: OPK) and The Frost Group.
BioZone Pharmaceuticals, Inc. Completes Balance Sheet Enhancement
Marketwire - Tue Dec 24, 7:00AM CST
BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) announced today that it has completed an enhancement of its balance sheet by eliminating remaining outstanding convertible notes. In the recent transaction, holders of convertible notes with approximately $2.5 million of principal and accrued interest exchanged their securities for shares of common stock. OPKO Health Inc. (NYSE: OPK), a principal shareholder of BioZone Pharmaceuticals and one of the note holders that converted its notes, expressed the view through its Chairman and CEO, Dr. Phillip Frost, that it is optimistic that the planned acquisition of Cocrystal Discovery will enhance shareholder value and enhance BioZone's future prospects as a high growth biotech company.
BioZone Pharmaceuticals, Inc. Enhances Balance Sheet
Marketwire - Mon Dec 02, 7:46AM CST
BioZone Pharmaceuticals, Inc. (OTCQB: BZNE) announced today that it has enhanced its balance sheet significantly by eliminating outstanding convertible preferred stock. In the recent transaction, holders of convertible preferred stock, with a stated value of $3.5 million and a 10% dividend, exchanged their securities for shares of common stock. Key holders expressed the view that the recently announced merger with Cocrystal Discovery, Inc. is a significant positive development for the Company.
Biozone Pharmaceuticals signs Letter of Intent to reverse merge with Cocrystal Discovery
M2 - Thu Nov 28, 4:44AM CST
Biozone Pharmaceuticals Inc (OTCBB:BZNE) announced on Wednesday its agreement to the terms and signed a Letter of Intent to merge with Cocrystal Discovery Inc, a biotechnology company developing antiviral therapeutics for human diseases.
Biozone Pharmaceuticals Announces Executed Letter of Intent to Merge With Cocrystal Discovery Inc.
Marketwire - Wed Nov 27, 7:00AM CST
Biozone Pharmaceuticals, Inc. (OTCBB: BZNE) today announced that it has agreed to terms and signed a Letter of Intent to merge with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases. Cocrystal Discovery has breakthrough technologies that enable the creation of first- and best-in-class antivirals.
LEVI & KORSINSKY, LLP Notifies Investors of BIOZONE PHARMACEUTICALS, INC. of Claims of Breaches of Fiduciary Duty by Board of the Company in Connection with the Sale of Assets to MusclePharm Corporation
Business Wire - Tue Nov 19, 12:11PM CST
Levi & Korsinsky notifies investors of Biozone Pharmaceuticals, Inc. ("Biozone" or the "Company"
(Nasdaq: BZNE) of possible breaches of fiduciary duty and other violations of state law in connection with the sale of Company assets to MusclePharm Corporation ("MusclePharm" (OTCQB: MSLP). Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of the Biozone Pharmaceuticals, Inc. Proposed Asset Sale to MusclePharm Corporation
Business Wire - Tue Nov 19, 7:17AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether the Board of Directors of Biozone Pharmaceuticals, Inc. (Nasdaq: BZNE) breached its fiduciary duties in connection with the Company's proposed sale of assets to MusclePharm Corporation (OTCQB: MSLP).
Equity Reports on BZNE, NNRX and ENIP
ACCESSWIRE - Thu Nov 14, 4:16AM CST
Biozone Pharmaceuticals Inc. (OTC:BZNE), Nutranomics Inc. (OTC:NNRX) and Endeavor IP Inc. (OTC:ENIP) have been added to our watch list.
Biozone Announces First Step in Strategic Transition
Marketwire - Wed Nov 13, 2:19PM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE), a manufacturer of over-the-counter (OTC) pharmaceuticals, and skin care, cosmetic and beauty products, and developer of proprietary drug delivery platforms, issued the following Letter to Shareholders from Elliot Maza, Chief Executive Officer and CFO of the company.
MusclePharm to Acquire BioZone Pharmaceuticals' QuSomes(R) Technology and Manufacturing Facilities
Marketwire - Wed Nov 13, 7:03AM CST
MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm"
, a leading international, award-winning sports nutrition company, announced today it has signed a definitive asset purchase agreement with BioZone Pharmaceuticals, Inc. ("BioZone" to acquire substantially all of the assets of BioZone and its subsidiaries. 
